검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nivolumab and Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma, Non-Hodgkin |
Overview Indication | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | biomarkers), bulk RNA sequencing, and targeted qPCR |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database.. Cancer remains one of the leading is associated with of death globally. This study analyzed adverse drug event (ADE) signals and potential factors associated with reporting in ipilimumab and nivolumab-treated cancer data from the Food and Drug Administration's (FDA) A… |
Clinical Primary efficacy | ORR 61.3% |
Clinical ORR | 61.3% |
Clinical Result source | ClinicalTrials.gov NCT04026412 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Nivolumab and Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma, Non-Hodgkin |
Overview Indication | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint blockade-mediated eradication of bone metastasis: case report |
MoA Biomarker | biomarkers), bulk RNA sequencing, and targeted qPCR |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database.. Cancer remains one of the leading is associated with of death globally. This study analyzed adverse drug event (ADE) signals and potential factors associated with reporting in ipilimumab and nivolumab-treated cancer data from the Food and Drug Administration's (FDA) A… |
Clinical Primary efficacy | ORR 61.3% |
Clinical ORR | 61.3% |
Clinical Result source | ClinicalTrials.gov NCT04026412 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교